NEPA300 was significantly more effective than PALO and numerically better than APR + OND for all secondary efficacy endpoints of no emesis , no significant nausea , and complete protection ( CR plus no significant nausea ) rates during the acute ( 0-24 h ) , delayed ( 25-120 h ) , and overall phases .